gopubmed logo
 
find other proteinsAll proteins
GoPubMed Proteins lists recent and important papers and reviews for proteins. Page last changed on 19 Aug 2016.

Monoamine oxidase B

MAO-B, monoamine oxidase B, monoamine oxidase type B
The protein encoded by this gene belongs to the flavin monoamine oxidase family. It is a enzyme located in the mitochondrial outer membrane. It catalyzes the oxidative deamination of biogenic and xenobiotic amines and plays an important role in the metabolism of neuroactive and vasoactive amines in the central nervous sysytem and peripheral tissues. This protein preferentially degrades benzylamine and phenylethylamine. [provided by RefSeq, Jul 2008] (from NCBI)
Top mentioned proteins: Monoamine Oxidase, CAN, HAD, AGE, ACID
Papers using MAO-B antibodies
Development and characterization of a conditional mitochondrial complex I assembly system.
Supplier
Bush Ashley, In PLoS ONE, 2003
... Human MAO-B cDNA was cloned into pBIG (Clontech) at the PstI and ...
Papers on MAO-B
AChE inhibition-based multi-target-directed ligands, a novel pharmacological approach for the symptomatic and disease-modifying therapy of Alzheimer's disease.
New
Chen et al., Shanghai, China. In Curr Neuropharmacol, Feb 2016
Herein, we delineated the catalytic and non-catalytic functions of AChE, and summarized the works of our group and others in research and development of novel AChEI-based multi-target-directed ligands (MTDLs), such as dual binding site AChEIs and multi-target AChEIs inhibiting Aβ aggregation, regulating Aβ procession, antagonizing PAF receptor, scavenging oxygen radical, chelating metal ions, inhibiting MAO-B, blocking NMDA receptor and others.
Drug design, synthesis, in vitro and in silico evaluation of selective monoaminoxidase B inhibitors based on 3-acetyl-2-dichlorophenyl-5-aryl-2,3-dihydro-1,3,4-oxadiazole chemical scaffold.
New
Maccioni et al., Cagliari, Italy. In Eur J Med Chem, Jan 2016
UNASSIGNED: With the aim to identify new, potent and selective monoamine oxidase B (MAO-B) inhibitors, molecular interaction field analysis has been applied to a MAO-B complex with 3-acetyl-2,5-diaryl-2,3-dihydro-1,3,4-oxadiazole chemical structure, known as a privileged scaffold for this target.
Novel (Hetero)arylalkenyl propargylamine compounds are protective in toxin-induced models of Parkinson's disease.
New
Sperlágh et al., Budapest, Hungary. In Mol Neurodegener, Dec 2015
Here we report the effects of a novel series of potent and selective MAO-B inhibitory (hetero)arylalkenylpropargylamine compounds having protective properties against the supraadditive effect of mitochondrial dysfunction and oxidative stress.
Parkinson's disease: fewer treatment withdrawals with levodopa.
New
In Prescrire Int, Dec 2015
In mid-2015, interim results of a randomised trial conducted in the routine care setting, involving 1620 patients with newly diagnosed Parkinson's disease, showed that levodopa was slightly more effective in terms of mobility than dopamine agonists or MAO-B inhibitors, after a median follow-up of 3 years.
Safinamide for symptoms of Parkinson's disease.
Review
New
Müller, Berlin, Germany. In Drugs Today (barc), Nov 2015
Ideal candidates for the balance of these neurotransmitter deficits are compounds like safinamide with broad mechanisms of action such as reversible monoamine oxidase type B inhibition, blockage of voltage-dependent sodium channels, modulation of calcium channels and of glutamate release.
Contribution of Monoamine Oxidase Inhibition to Tobacco Dependence: A Review of the Evidence.
Review
New
Hogg, Genève, Switzerland. In Nicotine Tob Res, Nov 2015
RESULTS: The identified data show a clear association between smoking and lower density of MAO-A and MAO-B binding sites in the brains of smokers and strong evidence that MAO is inhibited by a substance or substances in, or derived from, tobacco smoke.
Monoamine Oxidase Inhibitory Action of Chalcones: A Mini Review.
Review
New
Jayaprakash et al., India. In Cent Nerv Syst Agents Med Chem, Nov 2015
Many of the studies clearly revealed that most of the chalcones showed selective, reversible and potent MAO-B inhibition compared to MAO-A.
New treatments for levodopa-induced motor complications.
Review
New
Ferreira et al., Toulouse, France. In Mov Disord, Oct 2015
Positive results were also obtained with a new monoamine oxidase B (MAO-B) inhibitor (safinamide) and a catechol-O-methyltransferase COMT inhibitor (opicapone).
Rasagiline for the treatment of Parkinson's disease: an update.
Review
Torti et al., Roma, Italy. In Expert Opin Pharmacother, 2014
INTRODUCTION: Rasagiline is a potent, selective, irreversible Monoamine Oxidase-B (MAO-B) inhibitor, developed to prolong the action of dopamine in the brain.
In Vitro and in Vivo Neuroprotective Effects of Walnut (Juglandis Semen) in Models of Parkinson's Disease.
Oh et al., Seoul, South Korea. In Int J Mol Sci, 2014
MAO (and particularly monoamine oxidase B (MAO-B)) participates in the generation of reactive oxygen species (ROS), such as hydrogen peroxide that are toxic to dopaminergic cells and their surroundings.
Long-term effectiveness of dopamine agonists and monoamine oxidase B inhibitors compared with levodopa as initial treatment for Parkinson's disease (PD MED): a large, open-label, pragmatic randomised trial.
Impact
Clarke et al., In Lancet, 2014
BACKGROUND: Whether initial treatment for Parkinson's disease should consist of levodopa, dopamine agonists, or monoamine oxidase type B inhibitors (MAOBI) is uncertain.
GABA from reactive astrocytes impairs memory in mouse models of Alzheimer's disease.
Impact
Lee et al., Taejŏn, South Korea. In Nat Med, 2014
Here, we show that reactive astrocytes aberrantly and abundantly produce the inhibitory gliotransmitter GABA by monoamine oxidase-B (Maob) and abnormally release GABA through the bestrophin 1 channel.
Pharmacological treatment of Parkinson disease: a review.
Review
Impact
Lang et al., Hamilton, Canada. In Jama, 2014
RESULTS: Although levodopa is the most effective medication available for treating the motor symptoms of Parkinson disease, in certain instances (eg, mild symptoms, tremor as the only or most prominent symptom, aged <60 years) other medications (eg, monoamine oxidase type B inhibitors [MAOBIs], amantadine, anticholinergics, β-blockers, or dopamine agonists) may be initiated first to avoid levodopa-related motor complications.
Comparative platelet proteome analysis reveals an increase of monoamine oxidase-B protein expression in Alzheimer's disease but not in non-demented Parkinson's disease patients.
GeneRIF
Umlauf et al., Vienna, Austria. In J Proteomics, 2012
Mao-B platelet protein level may serve as a biomarker for age-related dementia, especially AD.
The 'gating' residues Ile199 and Tyr326 in human monoamine oxidase B function in substrate and inhibitor recognition.
GeneRIF
Edmondson et al., Atlanta, United States. In Febs J, 2011
results demonstrate that the bipartite cavity structure in MAO B plays an important role in substrate and inhibitor recognition to distinguish its specificities from those of MAO A
Structural properties of human monoamine oxidases A and B.
Review
GeneRIF
Edmondson et al., Pavia, Italy. In Int Rev Neurobiol, 2010
[review] Although the crystal structure of human MAO-A is monomeric while MAO-B is dimeric, both enzymes are dimeric in their membrane-bound forms.
Behavioral outcomes of monoamine oxidase deficiency: preclinical and clinical evidence.
Review
GeneRIF
Shih et al., Los Angeles, United States. In Int Rev Neurobiol, 2010
[review] While MAO-B primarily serves in the catabolism of 2-phenylethylamine and contributes to the degradation of other trace amines and dopamine, MAO-A has high affinity for serotonin and norepinephrine.
Association study of monoamine oxidase A/B genes and schizophrenia in Han Chinese.
GeneRIF
Hu et al., Xi'an, China. In Behav Brain Funct, 2010
Results suggest MAOB is a susceptibility gene for schizophrenia in Han Chinese.
Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial.
Impact
LARGO study group et al., Toulouse, France. In Lancet, 2005
BACKGROUND: Rasagiline mesylate is a novel drug for Parkinson's disease with selective, irreversible monoamine oxidase B (MAO-B) inhibitor activity, and is effective as monotherapy in early disease.
Inhibition of monoamine oxidase B in the brains of smokers.
Impact
Cilento et al., New York City, United States. In Nature, 1996
Here we report that brains of living smokers show a 40% decrease in the level of monoamine oxidase B (MAO B; EC 1.4.3.4) relative to non-smokers or former smokers.
share on facebooktweetadd +1mail to friends